Reporting macrolide-resistant Mycoplasma pneumoniae: a diagnostic obligation?

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Macrolide-resistant Mycoplasma pneumoniae (MRMP) is a growing global health concern, with increasing detection in the United States.
• Resistance in M. pneumoniae is primarily caused by 23S rRNA gene mutations, detectable via molecular assays on respiratory samples.
• Macrolide resistance is linked to prolonged illness, increased healthcare use, and delayed effective treatment.

Purpose of the Study:

• To highlight the clinical and public health implications of MRMP.
• To emphasize the need for improved diagnostic and reporting of macrolide resistance in M. pneumoniae.
• To address the gap in current commercial diagnostic assays regarding resistance detection.

Main Methods:

• Review of existing literature on MRMP prevalence, mechanisms, and clinical impact.
• Analysis of the role of molecular assays in detecting 23S rRNA mutations.
• Evaluation of the current limitations of commercially available diagnostic assays.

Main Results:

• Macrolide resistance in M. pneumoniae is associated with poorer clinical outcomes and increased antibiotic exposure.
• Molecular assays can reliably detect resistance markers in respiratory samples.
• Many commercial diagnostic tests fail to detect or report MRMP, contributing to diagnostic and stewardship gaps.

Conclusions:

• Accurate and timely detection of MRMP is crucial for effective patient management and antimicrobial stewardship.
• Enhanced diagnostic capabilities and routine reporting of resistance markers are needed.
• Closing the existing gaps will improve empiric therapy, outbreak recognition, and overall patient care.